<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.0 20120330//EN" "http://jats.nlm.nih.gov/publishing/1.0/JATS-journalpublishing1.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" article-type="article-commentary" dtd-version="1.0" xml:lang="en">
<front>
<journal-meta>
<journal-id journal-id-type="issn">1043-3155</journal-id>
<journal-id journal-id-type="nlm-ta">Pediatr Neurol Briefs</journal-id>
<journal-id journal-id-type="pmc">pedneurbriefs</journal-id>
<journal-id journal-id-type="iso-abbrev">Pediatr Neurol Briefs</journal-id>
<journal-title-group>
<journal-title>Pediatric Neurology Briefs</journal-title>
<abbrev-journal-title>Pediatr Neurol Briefs</abbrev-journal-title>
</journal-title-group>
<issn pub-type="epub">2166-6482</issn>
<issn pub-type="ppub">1043-3155</issn>
<issn-l>2166-3155</issn-l>
<publisher>
<publisher-name>Pediatric Neurology Briefs Publishers</publisher-name>
<publisher-loc>Chicago, IL, USA</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="publisher-id">PNB-6-93-a</article-id>
<article-id pub-id-type="doi">10.15844/pedneurbriefs-6-12-6</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Seizure Disorders</subject>
</subj-group>
<subj-group subj-group-type="Discipline-v2">
<subject>Neurology</subject>
<subject>Pediatrics</subject>
<subject>Nervous System Diseases</subject>
<subject>Child Development</subject>
<subject>Brain Diseases</subject>
<subject>Neurosurgery</subject>
<subject>Child</subject>
<subject>Infant</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Amantadine in Absence Epilepsy</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-0173-7931</contrib-id>
<name>
<surname>Millichap</surname>
<given-names>J. Gordon</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="AF0001">1</xref>
<xref ref-type="aff" rid="AF0002">2</xref>
<xref ref-type="corresp" rid="cor1">&#x002A;</xref>
</contrib>
</contrib-group>
<aff id="AF0001">
<label>1</label>Division of Neurology, Children&#x0027;s Memorial Hospital, Chicago, IL</aff>
<aff id="AF0002">
<label>2</label>Departments of Pediatrics and Neurology, Northwestern University Feinberg School of Medicine, Chicago, IL</aff>
<author-notes>
<corresp id="cor1"><label>&#x002A;</label>Correspondence: Dr. J. Gordon Millichap, E-mail: <email xlink:href="jgmillichap@northwestern.edu">jgmillichap@northwestern.edu</email>
</corresp>
</author-notes>
<pub-date date-type="pub" publication-format="print">
<month>12</month>
<year>1992</year>
</pub-date>
<pub-date date-type="pub" publication-format="electronic">
<day>01</day>
<month>07</month>
<year>2016</year>
</pub-date>
<volume>6</volume>
<issue>12</issue>
<fpage>93</fpage>
<lpage>93</lpage>
<permissions>
<copyright-statement>Copyright: &#x00A9; 1992 The Author(s)</copyright-statement>
<copyright-year>1992</copyright-year>
<license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/4.0/">
<license-p>This work is licensed under the <uri xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution 4.0 International License</uri>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p>
</license>
</permissions>
<related-article id="R1" related-article-type="commentary-article" ext-link-type="doi" xlink:href="10.1016/s0022-3476(05)81922-5" vol="121" page="819">
<article-title>Effect of add-on amantadine therapy for refractory absence epilepsy</article-title>
</related-article>
<abstract abstract-type="web-summary" specific-use="electronic-only">
<p>Refractory absence epilepsy in 4 children was treated with amantadine as an add-on drug at the Tel Aviv University Sackler School of Medicine, Israel.</p>
</abstract>
<kwd-group>
<kwd>Amantadine</kwd>
<kwd>Minor Motor Seizures</kwd>
<kwd>Absence Seizures</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<p>Refractory absence epilepsy in 4 children was treated with amantadine as an add-on drug at the Tel Aviv University Sackler School of Medicine, Israel. The patients responded within 1 week and remained free of symptoms for 27-36 months without adverse effects. The dosage was 5-7 mg/kg per day given twice a day up to a maximum of 200 mg daily. [<xref ref-type="bibr" rid="CIT0001">1</xref>]</p>
<disp-quote>
<p><bold>COMMENT.</bold> Amantadine was initially used by Shields et al. in the treatment of 10 children with minor motor seizures refractory to medications. Myoclonic seizures and atypical absence seizures responded well. [<xref ref-type="bibr" rid="CIT0002">2</xref>]</p>
</disp-quote>
</body>
<back>
<ref-list>
<ref id="CIT0001">
<label>1</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shahar</surname>
<given-names>EM</given-names>
</name>
<name>
<surname>Brand</surname>
<given-names>N</given-names>
</name>
</person-group>
<article-title>Effect of add-on amantadine therapy for refractory absence epilepsy</article-title>
<source>J Pediatr</source>
<year>1992</year>
<month>Nov</month>
<volume>121</volume>
<issue>5 Pt 1</issue>
<fpage>819</fpage>
<lpage>821</lpage>
<pub-id pub-id-type="doi">10.1016/s0022-3476(05)81922-5</pub-id>
<pub-id pub-id-type="pmid">1432438</pub-id>
</element-citation>
</ref>
<ref id="CIT0002">
<label>2</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shields</surname>
<given-names>WD</given-names>
</name>
<name>
<surname>Lake</surname>
<given-names>JL</given-names>
</name>
<name>
<surname>Chugani</surname>
<given-names>HT</given-names>
</name>
</person-group>
<article-title>Amantadine in the treatment of refractory epilepsy in childhood: an open trial in 10 patients</article-title>
<source>Neurology</source>
<year>1985</year>
<month>Apr</month>
<volume>35</volume>
<issue>4</issue>
<fpage>579</fpage>
<lpage>581</lpage>
<pub-id pub-id-type="pmid">3920549</pub-id>
</element-citation>
</ref>
</ref-list>
</back>
</article>